



Elan  
Drug  
Technologies



## Commercialised products

**Elan Drug Technologies has successfully developed improved formulations of 35 products which have subsequently been launched in 100+ countries.**

In the U.S. since 2001, 11 products have been launched that utilise our technologies, making us the most productive drug technology company during the period.

Our 35 launched products cover such therapeutic categories as CNS, Cardiovascular and Immunosuppression.

**Some of the products developed using Elan Drug Technologies' proprietary technologies are:**



Once daily, novel dual release morphine sulphate, marketed in U.S.



Oral table form of aprepitant, a poorly water soluble compound, marketed in U.S. and Internationally.



Once daily dexmethylphenidate for the treatment of Attention Deficit Hyperactivity Disorder, marketed by Novartis in US, using SODAS® technology.



# Elan Drug Technologies



## **HERBESSER® R**

Once daily, diltiazem product , marketed in Japan.



Invega® Sustenna™ once monthly extended release injectable formulation that incorporates the NanoCrystal® technology was approved by the FDA in July 2009 and is marketed by Janssen in the US.



Once daily extended release fluvoxamine maleate capsules for U.S. market using SODAS® technology.



Concentrated oral suspension of megestrol acetate utilising NanoCrystal® technology, marketed in the U.S.



A once daily form of naproxen sodium using the Elan Drug Technologies IPDAS® matrix technology, which allows for rapid disintegration and microdispersion in the gastrointestinal tract and reduced gastro-intestinal side effects normally seen with naproxen. Currently marketed in U.S. and Canada.



Oral tablet form of poorly water soluble rapamycin compound, marketed in U.S. and Internationally.



Elan  
Drug  
Technologies



## Ritalin<sup>®</sup> LA

Extended-release formulation of methylphenidate with a bi-modal release profile, marketed in U.S.

## Theodur<sup>®</sup>

Twice-daily, sustained-release theophylline, marketed in Japan.



New formulation fenofibrate, which can be taken without regard to food, launched in the U.S. by Abbott.



Once-daily extended release, chronotherapeutic verapamil for U.S. market administered at bedtime.